UA104869C2 - Фармацевтичні композиції, що містять ліганди рецептора дофаміну - Google Patents

Фармацевтичні композиції, що містять ліганди рецептора дофаміну

Info

Publication number
UA104869C2
UA104869C2 UAA201101837A UAA201101837A UA104869C2 UA 104869 C2 UA104869 C2 UA 104869C2 UA A201101837 A UAA201101837 A UA A201101837A UA A201101837 A UAA201101837 A UA A201101837A UA 104869 C2 UA104869 C2 UA 104869C2
Authority
UA
Ukraine
Prior art keywords
heading
receptor ligands
dopamine receptor
normal
pharmaceutical formulations
Prior art date
Application number
UAA201101837A
Other languages
English (en)
Russian (ru)
Inventor
Ранаджой Саркар
Махендра Г. Дедхія
Аніл Чхеттрі
Original Assignee
Ріхтер Гедеон Нірт.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41530841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA104869(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ріхтер Гедеон Нірт. filed Critical Ріхтер Гедеон Нірт.
Publication of UA104869C2 publication Critical patent/UA104869C2/uk

Links

Classifications

    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N25/00—Circuitry of solid-state image sensors [SSIS]; Control thereof
    • H04N25/70—SSIS architectures; Circuits associated therewith
    • H04N25/71—Charge-coupled device [CCD] sensors; Charge-transfer registers specially adapted for CCD sensors
    • H04N25/75—Circuitry for providing, modifying or processing image signals from the pixel array
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N25/00—Circuitry of solid-state image sensors [SSIS]; Control thereof
    • H04N25/70—SSIS architectures; Circuits associated therewith
    • H04N25/76—Addressed sensors, e.g. MOS or CMOS sensors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Multimedia (AREA)
  • Hospice & Palliative Care (AREA)
  • Signal Processing (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Винахід стосується фармацевтичної композиції у твердій оральній лікарській формі, що містить транс-1{4-[2-[4-(2,3-дихлорфеніл)-піперазин-1-іл]-етил]-циклогексил}-3,3-диметилсечовину або її фармацевтично прийнятну сіль та забуферювальний агент, бажано карбонат натрію, або ексипієнт, вибраний з прежелатинізованого крохмалю та безводного кальцію фосфату двозаміщеного, та відрізняється тим, що містить менш ніж приблизно 1 % (маса/маса) транс-4-[2-[4-(2,3-дихлорфеніл)-піперазин-1-іл]-етил]-циклогексиламіну або його фармацевтично прийнятної солі.
UAA201101837A 2008-07-16 2009-07-16 Фармацевтичні композиції, що містять ліганди рецептора дофаміну UA104869C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8105208P 2008-07-16 2008-07-16
PCT/US2009/050835 WO2010009309A1 (en) 2008-07-16 2009-07-16 Pharmaceutical formulations containing dopamine receptor ligands

Publications (1)

Publication Number Publication Date
UA104869C2 true UA104869C2 (uk) 2014-03-25

Family

ID=41530841

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201101837A UA104869C2 (uk) 2008-07-16 2009-07-16 Фармацевтичні композиції, що містять ліганди рецептора дофаміну

Country Status (33)

Country Link
US (6) US9056845B2 (uk)
EP (1) EP2317852B1 (uk)
JP (1) JP5774988B2 (uk)
KR (1) KR101612146B1 (uk)
CN (2) CN102118970A (uk)
AP (1) AP2975A (uk)
AU (1) AU2009270823B2 (uk)
BR (1) BRPI0916241A2 (uk)
CA (1) CA2730287C (uk)
CL (1) CL2011000091A1 (uk)
CO (1) CO6351689A2 (uk)
CY (1) CY1115994T1 (uk)
DK (1) DK2317852T3 (uk)
EA (1) EA025636B1 (uk)
EC (1) ECSP11010834A (uk)
ES (1) ES2532636T3 (uk)
GE (1) GEP20146052B (uk)
HR (1) HRP20150196T1 (uk)
IL (1) IL210615A (uk)
MA (1) MA32568B1 (uk)
MX (1) MX2011000622A (uk)
MY (1) MY156288A (uk)
NI (1) NI201100016A (uk)
NZ (1) NZ590852A (uk)
PL (1) PL2317852T3 (uk)
PT (1) PT2317852E (uk)
RS (1) RS53866B1 (uk)
SG (1) SG192507A1 (uk)
SI (1) SI2317852T1 (uk)
SM (1) SMT201500063B (uk)
UA (1) UA104869C2 (uk)
WO (1) WO2010009309A1 (uk)
ZA (1) ZA201101134B (uk)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0700353A2 (en) 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
US7875610B2 (en) 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
CA2715760C (en) * 2008-02-21 2017-06-13 Mitsubishi Tanabe Pharma Corporation Solid preparation for oral administration of cariprazine hydrochloride
SG192507A1 (en) 2008-07-16 2013-08-30 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
US8717044B2 (en) 2010-04-23 2014-05-06 Apple Inc. Charging systems with direct charging port support and extended capabilities
WO2014031162A1 (en) 2012-08-20 2014-02-27 Forest Laboratories Holdings Limited Crystalline form of carbamoyl-cyclohexane derivatives
EP2990029A1 (en) * 2014-08-29 2016-03-02 Sandoz Ag Pharmaceutical compositions comprising Canagliflozin
CN106560179B (zh) * 2015-09-30 2020-02-21 石药集团中奇制药技术（石家庄）有限公司 盐酸卡利拉嗪药物组合物及其制备方法
EP3231418A1 (en) * 2016-04-14 2017-10-18 Richter Gedeon Nyrt. Granule formulation for oral administration
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
CN107970217A (zh) * 2016-10-25 2018-05-01 浙江京新药业股份有限公司 卡利拉嗪口腔崩解片及其制备方法
HUP1700253A1 (hu) 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
CN109589315A (zh) * 2017-10-01 2019-04-09 北京万全德众医药生物技术有限公司 卡利拉嗪-亲水性材料共混物固体制剂的制备方法
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
HU231500B1 (hu) 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
HUP2200312A1 (hu) * 2022-08-05 2024-02-28 Richter Gedeon Nyrt Kariprazin tartalmú szájban diszpergálódó tabletta

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666911A (en) 1981-07-14 1987-05-19 Taiho Pharmaceutical Company Limited Allophanoylpiperazine compound and analgesic composition containing same as active ingredient
DE3540150A1 (de) 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4880797A (en) 1986-03-20 1989-11-14 Banyu Pharmaceutical Co., Ltd. Cephalosporin derivatives and antibacterial agents
JPH01199977A (ja) 1987-11-16 1989-08-11 Mochida Pharmaceut Co Ltd セファロスポリン誘導体の結晶、その製造法およびそれらを有効成分とする医薬組成物
GB8802622D0 (en) 1988-02-05 1988-03-02 Glaxo Group Ltd Chemical compound
US5047406A (en) 1989-12-06 1991-09-10 Warner-Lambert Co. Substituted cyclohexanols as central nervous system agents
US4957921A (en) 1989-12-06 1990-09-18 Warner-Lambert Company Substituted cyclohexanols as central nervous system agents
JPH04275280A (ja) 1991-03-04 1992-09-30 Nippon Chem Ind Co Ltd ４ｈ−２，３−ジヒドロ−２−イミノ−１，３−ベンゾチアジン−４−オン類の製造方法
JPH0532586A (ja) 1991-07-26 1993-02-09 Mitsubishi Petrochem Co Ltd ２，６−ナフタレンジカルボン酸の製造方法
DE4141268A1 (de) * 1991-12-14 1993-06-17 Merck Patent Gmbh Pharmazeutische zubereitung
JPH05310745A (ja) 1992-05-13 1993-11-22 Takeda Chem Ind Ltd ジエラジラクトンおよび抗炎症剤
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US20010009912A1 (en) 1995-02-10 2001-07-26 Christos Tsaklakidis New derivatives of pyridil piperazine or pyridazinyl piperazyl, process for production thereof and medicaments containing these compounds
CA2227585A1 (en) * 1995-08-18 1997-02-27 Purdue Research Foundation Novel fused isoquinolines as dopamine receptor ligands
WO1997011070A1 (en) 1995-09-22 1997-03-27 Warner-Lambert Company Substituted cyclohexylamines as central nervous system agents
US5807575A (en) * 1997-02-14 1998-09-15 Rougier Inc. Manufacture of cross-linked amylose useful as a excipient for control release of active compounds
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
CA2326804C (en) 1998-03-31 2006-05-02 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
SE9802208D0 (sv) 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
CN1307563A (zh) 1998-06-30 2001-08-08 泽里新药工业株式会社 N－苯基－n′－苯丙基哌嗪衍生物及其制备方法
HU230440B1 (hu) * 1999-03-31 2016-06-28 Janssen Pharmaceutica N.V Előgélesített keményítőt tartalmazó szabályozott felszabadulású készítmények
US6489341B1 (en) 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
US20070009931A1 (en) * 2000-08-04 2007-01-11 Kirsch Wolff M Negative correlation between IRP-2 and Transferrin receptor expression as a diagnostic of Alzheimer's disease
WO2002067924A1 (en) 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating bipolar disorder
CA2450315A1 (en) * 2001-06-13 2002-12-19 The Regents Of The University Of Michigan Dopamine receptor ligands and therapeutic methods based thereon
US6566550B2 (en) 2001-06-21 2003-05-20 Pfizer Inc Substituted aromatic ethers as inhibitors of glycine transport
HU227543B1 (en) 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
SE0200301D0 (sv) 2002-02-01 2002-02-01 Axon Biochemicals Bv Thio-carbostyril derivative
US6919342B2 (en) 2003-06-05 2005-07-19 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
HU227534B1 (en) * 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
WO2005041935A1 (en) * 2003-10-21 2005-05-12 Alpharma, Inc. Pharmaceutical formulations containing quetiapine
KR100641825B1 (ko) 2003-11-05 2006-11-02 주식회사 코오롱 4-바이페닐아세트산의 제조 방법
US20070099931A1 (en) * 2004-03-19 2007-05-03 Wyeth Pharmaceutical dosage forms and compositions
DE102004047517A1 (de) 2004-09-28 2006-03-30 Merck Patent Gmbh Neuartige Kristallform von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon, Hydrochlorid
AR052019A1 (es) 2004-10-15 2007-02-28 Bayer Pharmaceuticals Corp COMPUESTOS HETEROCICLICOS, PROCESOS DE PREPARACIoN Y MÉTODO PARA TRATAR ENFERMEDADES HIPERPROLIFERATIVAS
HUP0500170A3 (en) 2005-02-03 2007-11-28 Richter Gedeon Nyrt Piperazine derivatives, process for producing them and pharmaceutical compositions containing them
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
US8846100B2 (en) * 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
HU230748B1 (hu) 2007-05-11 2018-02-28 Richter Gedeon Nyrt Új piperazin só és előállítási eljárása
MY148643A (en) 2007-05-11 2013-05-15 Richter Gedeon Nyrt Solvate and crystalline forms of carbamoyl-cyclohexane derivatives
HUP0700353A2 (en) 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
HUP0700369A2 (en) 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
HUP0700370A2 (en) 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment of acute mania
CA2694887A1 (en) 2007-08-01 2009-02-05 Henriette Husum Bak-Jensen Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
PL2185155T3 (pl) 2007-08-03 2018-03-30 Richter Gedeon Nyrt. Kompozycje farmaceutyczne zawierające ligandy receptora dopaminy i sposoby leczenia z zastosowaniem ligandów receptora dopaminy
US7875610B2 (en) 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
CA2715760C (en) * 2008-02-21 2017-06-13 Mitsubishi Tanabe Pharma Corporation Solid preparation for oral administration of cariprazine hydrochloride
SG192507A1 (en) 2008-07-16 2013-08-30 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands
HU229858B1 (en) 2008-12-17 2014-10-28 Richter Gedeon Nyrt Process for the preparation of trans 4-amino-cyclohexyl acetic acid ethyl ester hcl
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
WO2010126527A1 (en) 2009-05-01 2010-11-04 Forest Laboratories Holdings Limited Methods of treating cns disorders
US20110117214A1 (en) 2009-11-16 2011-05-19 Auspex Pharmaceuticals, Inc. Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
WO2013169101A1 (en) 2012-05-07 2013-11-14 Echo Pharmaceuticals B.V. Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate
WO2014031162A1 (en) 2012-08-20 2014-02-27 Forest Laboratories Holdings Limited Crystalline form of carbamoyl-cyclohexane derivatives
HU231227B1 (hu) 2012-11-29 2022-03-28 Richter Gedeon Nyrt. Transz-4-{2-[4-(2,3-diklórfenil)-piperazin-1-il]-etil}N,N-dimetilkarbamoil-ciklohexilamin skizofrénia negatív tüneteinek kezelésére
ITMI20131693A1 (it) 2013-10-14 2015-04-15 Chemo Res S L Derivati della 1,4-cicloesilammina e loro preparazione
HUE036035T2 (hu) 2013-12-13 2018-06-28 Pf Medicament Kromon-származék mint dopamin-D3 receptor antagonista autizmus spektrum betegség kezelésében történõ alkalmazásra
CN105218484B (zh) 2015-09-14 2018-02-23 安徽省逸欣铭医药科技有限公司 酒石酸卡利拉嗪及其制备方法和医药用途
CN105330616B (zh) 2015-12-09 2017-09-26 苏州明锐医药科技有限公司 卡利拉嗪的制备方法
EP3231418A1 (en) 2016-04-14 2017-10-18 Richter Gedeon Nyrt. Granule formulation for oral administration
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
HUP1700253A1 (hu) 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder

Also Published As

Publication number Publication date
AU2009270823A1 (en) 2010-01-21
AP2011005549A0 (en) 2011-02-28
PT2317852E (pt) 2015-03-24
CO6351689A2 (es) 2011-12-20
SG192507A1 (en) 2013-08-30
EA025636B1 (ru) 2017-01-30
ZA201101134B (en) 2011-10-26
KR101612146B1 (ko) 2016-04-12
AU2009270823B2 (en) 2014-07-17
USRE49110E1 (en) 2022-06-21
CN102118970A (zh) 2011-07-06
CN104997743A (zh) 2015-10-28
EP2317852A1 (en) 2011-05-11
AP2975A (en) 2014-09-30
BRPI0916241A2 (pt) 2017-06-27
KR20110033852A (ko) 2011-03-31
MY156288A (en) 2016-01-29
ECSP11010834A (es) 2011-04-29
GEP20146052B (en) 2014-03-10
NI201100016A (es) 2011-08-03
CA2730287C (en) 2017-02-07
CL2011000091A1 (es) 2011-07-22
USRE49302E1 (en) 2022-11-15
PL2317852T3 (pl) 2015-05-29
EP2317852B1 (en) 2014-12-24
SI2317852T1 (sl) 2015-04-30
RS53866B1 (en) 2015-08-31
IL210615A0 (en) 2011-03-31
JP2011528374A (ja) 2011-11-17
HRP20150196T1 (hr) 2015-06-05
IL210615A (en) 2015-03-31
JP5774988B2 (ja) 2015-09-09
EP2317852A4 (en) 2011-10-05
CA2730287A1 (en) 2010-01-21
USRE47333E1 (en) 2019-04-02
MX2011000622A (es) 2011-04-07
WO2010009309A1 (en) 2010-01-21
EA201170198A1 (ru) 2011-08-30
US20100016334A1 (en) 2010-01-21
US9056845B2 (en) 2015-06-16
MA32568B1 (fr) 2011-08-01
NZ590852A (en) 2013-03-28
SMT201500063B (it) 2015-05-05
CY1115994T1 (el) 2017-01-25
US9056846B2 (en) 2015-06-16
ES2532636T3 (es) 2015-03-30
US20130040966A1 (en) 2013-02-14
DK2317852T3 (en) 2015-03-23
USRE47350E1 (en) 2019-04-16

Similar Documents

Publication Publication Date Title
UA104869C2 (uk) Фармацевтичні композиції, що містять ліганди рецептора дофаміну
MX2011006959A (es) Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
EP2582676A4 (en) POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS
MX336774B (es) Moduladores alostericos positivos de receptores m1 de la quinolina amida.
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
TN2011000437A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
MY161593A (en) Oral formulations of cytidine analogs and methods of use thereof
MY161088A (en) Agonists of gpr40
MA32898B1 (fr) Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
MX2012009079A (es) Formulaciones de rasagilina de liberación prolongada y usos de las mismas.
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
UA106200C2 (uk) Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину
MY152685A (en) Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments
WO2009117283A3 (en) Quinolizidinone m1 receptor positive allosteric modulators
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2012002209A (es) Formulaciones de liberacion controlada de compuestos de anabaseina y usos de los mismos.
MY152040A (en) Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
TN2011000018A1 (en) Pharmaceutical formulations containing dopamine receptor ligands